Inhibitor

(redirected from dipeptidyl peptidase-4 inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Legal, Wikipedia.

inhibitor

[in′hib·əd·ər]
(aerospace engineering)
A substance bonded, taped, or dip-dried onto a solid propellant to restrict the burning surface and to give direction to the burning process.
(chemistry)
A substance which is capable of stopping or retarding a chemical reaction; to be technically useful, it must be effective in low concentration.

Inhibitor

 

a circuit having m + n inputs and a single output, at which a signal can appear only when there are no signals on the m inputs (inhibiting). The other n inputs (principal) form one of the two logic connections, “AND” or “OR.” Inhibitors are used extensively in computers. They are very often understood to be a circuit having a single principal input and a single inhibiting input. A signal appears at the output of such a circuit when a signal is present on the principal input but there is none on the inhibiting input. Such an inhibitor is called an anticoincidence gate; its conventional representation is given in Figure 1.

Figure 1. Block diagram of an anticoincidence gate (inhibitor) with m — 1 and n 1:(A) principal input, (Q) inhibiting input, (Ga) anticoincidence gate

inhibitor

A substance added to paint to retard drying, skinning, mildew growth, etc. Also see corrosion inhibitor, inhibiting pigment, drying inhibitor.
References in periodicals archive ?
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 2014;35:992-1019.
Goto, "Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterolfed rabbits," Metabolism, vol.
Wong, "Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: a pilot study," Diabetes & Vascular Disease Research, vol.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
Chattipakorn, "Dipeptidyl peptidase-4 inhibitors and the ischemic heart: additional benefits beyond glycemic control," International Journal of Cardiology, vol.
Chang, "Dipeptidyl peptidase-4 inhibitor use is not associated with acute pancreatitis in high-risk type 2 diabetic patients: a nationwide cohort study," Medicine, vol.
Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged [greater than or equal to] 65 years.
The second study compared patients who began a two-drug combination regimen during 2007-2013, comprising 33,983 patients who began metformin plus a sulfonylurea and 7,864 who began metformin plus a dipeptidyl peptidase-4 inhibitor. The adjusted rate of all-cause mortality was a relative 36% higher among patients treated with a sulfonylurea, compared with those treated with a DPP-4 inhibitor, Dr.
Linagliptin (Tradjenta; B), a dipeptidyl peptidase-4 inhibitor taken orally, is indicated for type 2 diabetes.
Rabinovitch, "Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice," Diabetologia, vol.
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Albiero et al., "The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes mellitus.

Full browser ?